PAGE HEFNER: Open Payments
NPI 1023584323 · ROSSFORD, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 35 payments from 15 companies in 2025. Trend: 2023 $847 · 2024 $652 · 2025 $740
Food & beverage: $740
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $135 |
| ABBVIE INC. | 5 | $104 |
| Teva Pharmaceuticals USA, Inc. | 5 | $98 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Neurocrine BioSciences, Inc. | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
| Lundbeck LLC | 2 | $43 |
| UCB, Inc. | 2 | $39 |
| Amgen Inc. | 2 | $37 |
Products named: VRAYLAR, AUSTEDO XR, Wegovy, GEMTESA, INGREZZA, XIFAXAN, REXULTI, REPATHA.
Industry payments across OH — which companies pay providers there.
